DE68921034D1 - Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält. - Google Patents

Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.

Info

Publication number
DE68921034D1
DE68921034D1 DE68921034T DE68921034T DE68921034D1 DE 68921034 D1 DE68921034 D1 DE 68921034D1 DE 68921034 T DE68921034 T DE 68921034T DE 68921034 T DE68921034 T DE 68921034T DE 68921034 D1 DE68921034 D1 DE 68921034D1
Authority
DE
Germany
Prior art keywords
heterologous gene
replication
provirus
vector containing
competent hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68921034T
Other languages
English (en)
Inventor
William A Haseltine
Ernest Terwilliger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE68921034D1 publication Critical patent/DE68921034D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE68921034T 1988-09-27 1989-09-18 Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält. Expired - Lifetime DE68921034D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24991888A 1988-09-27 1988-09-27

Publications (1)

Publication Number Publication Date
DE68921034D1 true DE68921034D1 (de) 1995-03-23

Family

ID=22945570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921034T Expired - Lifetime DE68921034D1 (de) 1988-09-27 1989-09-18 Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.

Country Status (6)

Country Link
US (1) US6033902A (de)
EP (1) EP0361749B1 (de)
JP (1) JPH02211882A (de)
AT (1) ATE118247T1 (de)
CA (1) CA1336075C (de)
DE (1) DE68921034D1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE69032841T2 (de) * 1989-01-23 1999-05-12 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
EP0487587A1 (de) * 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5334498A (en) * 1992-08-18 1994-08-02 Arch Development Corporation Herpes simplex virus 1 UL13 gene product: methods and compositions
NZ331376A (en) * 1996-01-29 2000-03-27 Virologic Inc Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
DK1115290T3 (da) * 1998-10-01 2009-06-22 Univ Southern California Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
US7138231B2 (en) * 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20030108857A1 (en) * 2001-06-04 2003-06-12 Parkin Neil T. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU7268000A (en) * 1999-07-21 2001-02-13 Martin Heinkelein Method for quantization of the antiviral effect of antiviral active principles
CA2412217A1 (en) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Hiv-1 reporter viruses and their use in assaying anti-viral compounds
US6653081B2 (en) * 2000-06-12 2003-11-25 Virologic, Inc. Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
EP1283272B1 (de) * 2001-08-08 2013-11-13 Janssen R&D Ireland Verfahren und Mittel zur Bewertung einer gegen das HIV Hüllprotein (env) gerichteten Inhibitortherapie
US7384734B2 (en) * 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2491392A1 (en) * 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the replication capacity of a pathogenic virus
CN1688719A (zh) * 2002-07-01 2005-10-26 瓦罗洛吉克公司 确定致病性病毒对蛋白酶抑制剂易感性的组合物和方法
WO2004003514A2 (en) * 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
US7736848B2 (en) * 2002-09-30 2010-06-15 Fox Chase Cancer Center Cellular targets for treatment of retroviral infection
WO2005076893A2 (en) * 2004-02-06 2005-08-25 Virologic, Inc. Compositions and methods for determining the replication capacity of a pathogenic virus
WO2005094288A2 (en) * 2004-03-29 2005-10-13 Virologic, Inc. Compositions and methods for determining epistatic relationships between hiv mutations that affect replication capacity
US20060094020A1 (en) * 2004-10-29 2006-05-04 Parkin Neil T Methods and compositions for determining resistance or susceptibility of HIV-1 to stavudine
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2909324B1 (de) 2012-10-25 2020-02-26 Tocagen Inc. Retroviraler vektor mit mini-promoter-kassette
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015120459A2 (en) * 2014-02-10 2015-08-13 Nutech Ventures Live, attenuated vaccines and methods of making and using
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
EP0329671B1 (de) * 1986-11-01 1994-01-12 British Bio-Technology Limited Kugelförmige hybrid-hiv-antigene
FR2607518B1 (fr) * 1986-12-01 1989-10-20 Transgene Sa Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus
ATE126534T1 (de) * 1987-05-29 1995-09-15 Dana Farber Cancer Inst Inc Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.

Also Published As

Publication number Publication date
EP0361749A1 (de) 1990-04-04
CA1336075C (en) 1995-06-27
ATE118247T1 (de) 1995-02-15
JPH02211882A (ja) 1990-08-23
US6033902A (en) 2000-03-07
EP0361749B1 (de) 1995-02-08

Similar Documents

Publication Publication Date Title
DE68921034D1 (de) Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
DE3760912D1 (en) Retrovirus of the type hiv-2 capable of inducing aids, and the antigenic and nucleic acid components thereof
ATE241014T2 (de) Hiv-2 varianten
BG102041A (en) Oxidized heterocycles containing sulphonamide aspartylprotease inhibitors
IL88900A0 (en) Imidazoles,their preparation and pharmaceutical compositions containing them
GB2199328A (en) Translation of mrna
DK0887427T3 (da) Amplifikation og detektion af HIV-1 og/eller HIV-2
DK464578A (da) Fremgangsmaade til fremstilling af 3-substituerede og 6-substituerede 7-oxo-1-azabicyclo (3,2,0) hept-2-en-2-carxylsyrer eller amiier deraf
FR2351181A1 (fr) Alliages de fusion, notamment pour la realisation de protheses et d'implants
DK53990A (da) Fremgangsmaade til at frembringe en oxiderende flamme, en braender og anvendelsen af en braender
ATE172992T1 (de) Übergangsmetallverbindung
GB2046508B (en) Ring laser gyroscope anode
NO880935L (no) Fremgangmsaate for paavisning av hiv eller annet virus med lignende klinisk virkning.
IL85913A0 (en) Combination beam combiner and beam emitter for ring laser gyroscope
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
BR8804803A (pt) Processo de preparacao de um po fino supra-condutor,po ceramico e material ceramico sinterizado supra-condutor
ES498563A0 (es) Procedimiento de escarpado por un chorro de oxigeno y soplete multiforme para la utilizacion de este procedimiento.
DK152649C (da) Analogifremgangsmaade til fremstilling af en 4-oen-(3',4'-dihydroxybenzyliden)-aminomethylaacyklohexan-1-carboxylsyre og derivater deraf
DK161338C (da) Fremgangsmaade til fremstilling af 2-hydroxyaclacinomycin a, b og n eller syreadditionssalte deraf samt en rekombinant mikroorganisme til anvendelse derved
AR230999A1 (es) Medio de cultivo,para el desarrollo de virus de leucosis bovina,de para influencia 3 o de herpes suis en cultivo en suspencion,procedimiento para el desarrollo en dicho medio de cultivo y medio de diagnostico en base a los virus desarrollados
SU674730A1 (ru) Корчеватель-измельчитель
NO891691D0 (no) Rekombinant gag-forloeper for hiv.
IL56658A (en) Ring laser gyroscope with reduced "lock-in"
DK251780A (da) Fremgangsmaade til fremstilling af 1,3-dibrom-2,2-dimethyl-propan-1,3-dicarboxylsyre-derivater samt som mellemprodukter anvendelige 1,3-dibrom-2,2-dimethyl-propan-1,3-dicarboxylsyredichlorider og chlorid-estere
GB2044518B (en) Low loss apertures for ring laser gyros

Legal Events

Date Code Title Description
8332 No legal effect for de